Article
Hypoimmunogenic hPSC-derived cardiac organoids for immune evasion and heart repair
2025-04-09
Abstract excerpt
<h4>ABSTRACT</h4> Human pluripotent stem cell (hPSC)-derived cardiac therapies hold great promise for heart regeneration but face major translational barriers due to allogeneic immune rejection. Here, we engineered hypoimmunogenic hPSCs using a two-step CRISPR-Cas9 strategy: (1) B2M knockout, eliminating HLA class I surface expression, and (2) knock-in of HLA-E or HLA-G trimer constructs in the AAVS1 safe harbor...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 2c649637-440e-5c08-a7f2-71f3bc0e69ef
- DOI
- 10.1101/2025.04.09.648007
